rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PCVX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vaxcyte at jefferies global healthcare conference: adult vaccine path sharpens
      17h agoInvesting.comPCVXJEF
      S&P 500 Futures Fall in Premarket Trading; TELUS Corp., Vaxcyte Lead
      Nov 16Barron'sPCVXTU
      BTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)

      Tipranks Press Release.

      Nov 6The Globe and MailPCVX
      Vaxcyte SVP Elvia Cowan sells $182,753 in stock
      Nov 5Investing.comPCVX
      Vaxcyte evp Jim Wassil sells $137,024 in company stock
      Nov 4Investing.comPCVX
      Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 4Yahoo FinancePCVX
      InvestingPro predicted Vaxcyte’s 44% decline two years ago By Investing.com
      Nov 2Investing.comPCVX
      Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
      Oct 30Yahoo FinancePCVX
      iShares Russell 2000 (IWM) Adds Critical Metals and Vaxcyte on Oct. 27
      Oct 29Yahoo FinanceCRMLPCVX
      Cantor Fitzgerald reiterates Vaxcyte stock rating on OPUS-1 data
      Oct 19Investing.comPCVX
      Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)
      Oct 19Seeking AlphaPCVX
      Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
      Oct 14Yahoo FinancePCVX
      Cantor Fitzgerald sets Vaxcyte stock price target at $120
      Oct 12Investing.comPCVX
      Vaxcyte SVP Elvia Cowan sells $1.6 million in company stock
      Oct 11Investing.comPCVX
      Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares
      Oct 11Investing.comPCVX
      Vaxcyte Bolsters Capital Structure with New Offerings

      Tipranks Press Release.

      Oct 10The Globe and MailPCVX
      Vaxcyte closes $1.15 billion stock and convertible note offerings
      Oct 9Investing.comPCVX
      Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
      Oct 9Yahoo FinancePCVX
      Why Vaxcyte (PCVX) Is Getting Attention Again

      Vaxcyte (PCVX) has just raised roughly US$1b through concurrent common stock, pre funded warrant and convertible note offerings, following positive Phase 3 data for its VAX 31 pneumococcal vaccine candidate. Recent trading has been strong, with Vaxcyte’s share price at US$66.96 after a 7 day share price return of 17.68% and a year to date share price gain of 44.12%. The 1 year total shareholder return of 64.36% and 5 year total shareholder return of 175.56% point to momentum that has been...

      Oct 8Yahoo FinancePCVX
      Vaxcyte Prices $1 Billion Offerings of Stock, Prefunded Warrants, 2032 Notes
      Oct 7Yahoo FinancePCVX
      Vaxcyte prices $1 billion dual offering of stock and notes
      Oct 7Investing.comPCVX
      Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
      Oct 7Yahoo FinancePCVX
      Vaxcyte: VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 (NASDAQ:PCVX)

      Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead. Click for more on PCVX.

      Oct 6Seeking AlphaPCVX
      Biotechs Sell Off — These Are The Biggest Losers

      Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

      Oct 6Investor's Business DailyMRNAPCVXRVMD
      As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

      Key TakeawaysVaxcyte shares fell 10% after the company launched a $1 billion raise, split between $500 million of stock and $500 million of convertible notes, hours after its Phase 3 win. Raising now makes sense – as I noted yesterday – since VAX-31 isn’t due to be filed for approval until the first half of 2028 and Vaxcyte’s spending keeps climbing until then.

      Oct 6Yahoo FinancePCVX
      Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
      Oct 6Yahoo FinancePCVX
      Why is Vaxcyte stock sliding today?
      Oct 6Investing.comPCVX
      BofA raises Vaxcyte stock price target to $146 on OPUS-1 data
      Oct 6Investing.comPCVX
      Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxie

      Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to

      Oct 6BenzingaMRNANVAXPCVX
      Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

      Vaxcyte (NASDAQ:PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults. The randomized, double-blind, active-controlled study enrolled 4,047 U.S. adults, including 3,572

      Oct 6Yahoo FinancePCVX
      Vaxcyte announces $1 billion dual public offering
      Oct 6Investing.comPCVX
      NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

      Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.

      Oct 5Yahoo FinanceMRNANVAXPCVX
      Why is Vaxcyte stock sliding in after-hours trading today?
      Oct 5Investing.comPCVX
      Vaxcyte stock falls on $1B dual offering launch
      Oct 5Investing.comPCVX
      Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

      SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to b

      Oct 5Yahoo FinancePCVX
      BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
      Oct 5Investing.comPCVX
      PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

      In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.

      Oct 5Yahoo FinancePCVX
      Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more

      Here are some of the companies making headlines in midday trading.

      Oct 5CNBCMSFTPCVXBBDBBDO
      Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
      Oct 5Barron'sPCVXMRKPFE
      🔎 Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds Up in Study
      Oct 5WSJPCVX
      Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow (NASDAQ:PCVX) 2026-10-05
      Oct 5Seeking AlphaPCVX
      Why is Vaxcyte stock surging today?
      Oct 5Investing.comPCVX
      Intel, XP Inc., PTC, RXO, Vaxcyte, Western Digital, Cerebras, and More Stocks That Explain Today’s Market
      Oct 5Barron'sCBRSDKNGINTCMUPCVXQCOMWDCXPHOGRXO
      Vaxcyte stock hits 52-week high at 87.21 USD
      Oct 5Investing.comPCVX
      Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority

      Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.

      Oct 5Yahoo FinancePCVX
      Vaxcyte shares surge on late-stage vaccine trial success

      Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete...

      Oct 5Yahoo FinancePCVX
      Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market

      Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.

      Oct 5Investor's Business DailyPCVXMRKPFE
      RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday - RXO (NYSE:RXO)

      U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.

      Oct 5BenzingaPCVXPTCRXO
      Vaxcyte stock soars 50% on positive phase 3 vaccine data
      Oct 5Investing.comPCVX
      Vaxcyte Stock Hits New 52-Week High - Here’s Why - Vaxcyte (NASDAQ:PCVX)

      Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.

      Oct 5BenzingaPCVX

      This is the newest page. Registered accounts read further back.